Table 1 Patient reported baseline variables
Respondents | 245 | |
|---|---|---|
Median age (range) | 59 (27-88) | |
Method of cancer detection | Symptomatic | 161 (65.7%) |
Screen | 81 (33.1%) | |
Not answered | 3 (1.2%) | |
Time from surgery to completion of questionnaire | <6 months | 93 (38.0%) |
6-12 months | 50 (20.4%) | |
>12 months | 94 (38.4%) | |
Not answered | 8 (3.3%) | |
Stage of breast cancer | 1 | 88 (35.9%) |
2 | 69 (28.2%) | |
3 | 40 (16.3%) | |
Unknown | 48 (19.6%) | |
Hormone receptor positive breast cancer | Yes | 158 (64.5%) |
No | 27 (11.0%) | |
Don’t know | 52 (21.2%) | |
Not answered | 8 (3.3%) | |
Human epidermal growth factor receptor (HER-2) positive breast cancer | Yes | 54 (22.0%) |
No | 89 (36.3%) | |
Don’t know | 87 (35.5%) | |
Not answered | 15 (6.1%) | |
Triple negative breast cancer | Yes | 15 (6.1%) |
No | 114 (46.5%) | |
Don’t know | 85 (34.7%) | |
Not answered | 31 (12.7%) | |
Lymph node positive breast cancer | Yes | 103 (42.0%) |
No | 124 (50.6%) | |
Don’t know | 9 (3.7%) | |
Not answered | 9 (3.7%) | |